MBII Marrone Bio Innovations Inc

Marrone Bio Announces Introduction of New Synergistic Plant Health Product Available to Corn, Soybean and Wheat Growers

Marrone Bio Announces Introduction of New Synergistic Plant Health Product Available to Corn, Soybean and Wheat Growers

Bio-Based Plant Health Product Pacesetter™ Proven to Boost Yield and ROI to Farmers

DAVIS, Calif., April 07, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, today announced that Pacesetter™, a recently approved bio-based plant health product, is now available to corn, soybean and wheat growers in the United States.

Pacesetter acts synergistically with conventional fungicides to improve plant health and vigor, increasing yield by up to seven bushels per acre in soybeans and 13 bushels per acre in corn. The active ingredient in Pacesetter is a plant extract from Reynoutria sachalinensis, a compound that delivers multiple modes of action. When used with conventional fungicides, Pacesetter promotes root growth, and increases chlorophyll production in the crop, resulting in yield increases beyond that of a grower’s standard fungicide program. 

This foliar plant health product is the newest addition to MBI’s BioUnite™ portfolio, a science-based integrated pest management program that harnesses the power of biology with the performance of chemistry.

Pacesetter Field Trials

Twenty-four corn and soybean field trials were conducted in the Midwest during the 2019 crop year to assess the performance of Pacesetter when added to a grower’s standard fungicide program. The results have been positive; notably in soybeans where 82% of the time, when combined with a conventional fungicide, Pacesetter achieved higher yields than the grower’s standard fungicide program alone.

When Pacesetter’s 2019 soybean yield was combined with testing data from prior years, the yield was improved by an average of nearly four percent compared to the grower’s standard fungicide program without the use of Pacesetter. These results represent a 71% win rate and a four to one return on investment.

In corn, when the 2019 yield of Pacesetter was combined with testing data from prior years, the average yield increase was four bushels per acre versus the grower’s standard fungicide program without the use of Pacesetter. The return on investment was particularly significant for corn in yield-challenging environments where results showed a 6.25 bushels per acre increase.

"BioUnite™ increases value to growers by offering an integrated crop management program that increases yield and return on investment,” said Kevin Hammill, Chief Commercial Officer of Marrone Bio Innovations. “Pacesetter is the latest example of MBI providing incremental value to its customers through a strong portfolio of plant health products.”

Pacesetter, the newest addition to MBI’s biological product portfolio, received EPA approval in February 2020 and will be commercially available for the 2020 growing season, pending state approvals.

About Marrone Bio Innovations

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Pacesetter™, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP™ 110, Foramin®, UBP™ Seed Treatment, Foramin® ST.

Learn more about Marrone Bio Innovations at . We also use our investor relations website, , as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: , and .

Marrone Bio Innovations Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including, the potential of Pacesetter in row crops, weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.

Marrone Bio Innovations Contact:

Kevin Hammill, Chief Commercial Officer



1-530-750-2800

Investor Relations Contact:

Greg Falesnik, Managing Director

MZ Group – MZ North America

Main: 949-385-6449



Photos accompanying this announcement are available at:

EN
07/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Marrone Bio Innovations Inc

 PRESS RELEASE

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement wi...

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp. RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI’s stockholde...

 PRESS RELEASE

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Res...

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the ...

 PRESS RELEASE

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednes...

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations’ first quarter financial re...

 PRESS RELEASE

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 202...

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was ...

 PRESS RELEASE

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Cr...

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Crops Company poised for continued growth in a $6+ billion market¹ RALEIGH, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), has signed an agreement with Corteva Agriscience (NYSE: CTVA) that expands the opportunity for MBI technologies to be used on seeds sold by Corteva for row crops globally. Marrone Bio currently provides seed treatment solutions to Corteva for use throughout Europe. MBI introduced biological seed treatments as a sustainable alternative to control yield-robbing pests in the United States i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch